Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

73.750
-0.650-0.87%
Volume:2.18M
Turnover:158.78M
Market Cap:41.57B
PE:48.90
High:74.300
Open:73.800
Low:71.750
Close:74.400
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:1.03
T/O Rate:1.04%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.508
ROE:109.10%
ROA:39.01%
PB:4.28
PE(LYR):48.90
PS:4.44

Loading ...

HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty

Stock News
·
Sep 11

Remegen Announces Participation in Nasdaq-Style STAR Market Biopharma Sector Earnings Conference

Deep News
·
Sep 07

RemeGen Maintains Stable Share Base; Minor A-Share Buyback Adds to Treasury in August 2026

Bulletin Express
·
Sep 04

REMEGEN Discloses Cumulative Buyback of 41,000 A-Shares by End of August

Stock News
·
Sep 02

Executive Director Wang Yuxiao Reduces Stake in Remegen (09995) by 13,500 Shares at Approximately HK$81.54 Each

Stock News
·
Sep 02

Executive Director Wang Yuxiao Reduces Stake in Remegen with Share Sale

Stock News
·
Sep 01

RemeGen (SEHK:9995) Stock Profit Surge Meets Doubts Over Earnings Durability

Simply Wall St.
·
Aug 26

Citi Lifts REMEGEN Price Target to HK$127.7, Keeps Buy/High-Risk Call

Stock News
·
Aug 26

CLSA Raises REMEGEN Price Target to HK$144.8, Reiterates Outperform Rating on Strong Q2 Beat

Stock News
·
Aug 26

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Movement Alert|REMEGEN Rises 5.04% in Regular Trading, Interim Results Turn Profitable Amid Biotech Sector Rally

Market Focus
·
Aug 26

Market Sentiment Stabilizes as Sanctions Prove Largely Symbolic; Tech Benchmarks Surge on Potential Dovish Fed Signals

Stock News
·
Aug 25

Movement Alert|REMEGEN Rises 5.12% in Regular Trading, H1 Earnings Show Turnaround to Profitability with Revenue Surging Over 4x

Market Focus
·
Aug 25

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live
·
Aug 25

RemeGen turns profitable: H1 2026 revenue jumps 435.74% to RMB5.85 billion on AbbVie deal and core drug sales

Bulletin Express
·
Aug 24

Movement Alert|REMEGEN Falls 5.13% in Regular Trading, Market Questions Sustainability of One-Time Licensing Revenue Ahead of Interim Results

Market Focus
·
Aug 24

Movement Alert|REMEGEN Rises 5.2% in Regular Trading, Biotech Sector Rallies Ahead of Interim Results Release

Market Focus
·
Aug 20

RemeGen commits an additional US$30.00 million to OCBC structured deposit; aggregate wealth-management investment reaches US$100.00 million

Bulletin Express
·
Aug 18

Earning Preview: REMEGEN Q2 revenue is expected to increase by 691%, and institutional views are bullish

Earnings Agent
·
Aug 17

Stock Track | REMEGEN Soars 5.10% Intraday on H1 Profit Turnaround and AbbVie Licensing Deal

Stock Track
·
Aug 10